BAGO GROUP

About BAGO GROUP

The Bago Group's pharmaceutical products are internationally renowned for their quality and therapeutic effectiveness, supported by the strictest pharmacotechnical and clinical evaluations. Today Bago is a synonym for excellence in the markets where our products are sold. Our subsidiaries, strategically located in 21 Latin American, European and Asian countries, secure an efficient delivery of our products to over 45 countries worldwide.

  • SG
  • 2015
    On CPHI since
Company types
Distributor/Import Export
Manufacturer/Innovator
Contact info
Meet us at

CPHI Barcelona 2023

Fira Barcelona, Spain
24-26 October 2023

Products from BAGO GROUP (5)

  • ACTINERVAL® Carbamazepine

    Product ACTINERVAL® Carbamazepine

    Anticonvulsant with specific psychotropic and antineuralgic effect.INDICATIONS
    Epilepsy: In monotherapy or associated with other antiepileptic drugs, treatment of psychomotor or temporary seizures, tonic-clonic seizures (grand mal), mixed forms, focal seizures. In general, carbamazepine does not work ...
  • AZECAR® Acenocoumarol

    Product AZECAR® Acenocoumarol

    Azecar® contains as active substance Acenocoumarol, a coumarin derivative and vitamin K antagonist. It inhibits the gamma-carboxylation of certain glutamic acid molecules located at various sites near the terminal ends of coagulation factors II (prothrombin) VII, IX and X and of protein C or its cofactor, ...
  • BOSENTAL® Bosentan

    Product BOSENTAL® Bosentan

    INDICATIONS Pulmonary arterial hypertension (WHO Group I) in patients with functional class II to IV. Reduction of the number of new digital ulcers in patients with systemic sclerosis (scleroderma) with active ulcerative digital alteration, or history of digital ulcers in the last year. Strength/...
  • AZUMEL® Apremilast

    Product AZUMEL® Apremilast

    Indications:  • Psoriatic arthritis: Azumel® is indicated for the treatment of active psoriatic arthritis (PsA). • Psoriasis: Azumel® is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for phototherapy or systemic treatment. • ...
  • BRIOTAZ® Ambrisentan

    Product BRIOTAZ® Ambrisentan

    INDICATIONS:Briotaz 5 is indicated for the treatment of patients with pulmonary arterial hypertension (PAH) classified as World Health Organization (WHO) functional class II and III, to improve their exercise capacity. The efficacy of this drug has been demonstrated in idiopathic PAH (IPAH) and in PAH asso...

BAGO GROUP Resources (1)